IRIX earnings analysis
What we found in IRIX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Iridex reported Q2 revenue of $12.566 million and a diluted EPS loss of $0.07, missing consensus estimates of $13.587 million and a $0.01 loss. Revenue was up approximately 4.7% sequentially but down 10.2% year over year, with 19% Cyclo G6 growth to $3.9 million only partly offsetting Retina's decline to $6.5 million from $8.0 million. Management's full-year revenue outlook is $51 million-$53 million, below the prior $53 million-$55 million range, and the 10-Q adds a material governance risk involving the largest shareholder.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue improved sequentially, fell year over year
- Q2 revenue was $12.566 million, approximately 4.7% above Q1 revenue of $12 million but 10.2% below the prior-year quarter's $14 million.
- Cyclo G6 growth partly offsets Retina decline
- Cyclo G6 product-family revenue increased 19% year over year to $3.9 million, partially offsetting Retina revenue declining to $6.5 million from $8.0 million.
- Operating expenses declined 5%
- Operating expenses declined 5% year over year, indicating cost control despite the revenue shortfall.
- Operating cash flow turned positive
- The company reported positive operating cash flow in Q2, although the filing information provided does not disclose a dollar amount or free cash flow.
- Revenue outlook reset lower
- Full-year 2026 revenue guidance is $51 million-$53 million versus the prior $53 million-$55 million outlook, while adjusted operating expense guidance remains $19 million-$19.5 million.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Revenue and EPS missed estimates
- Q2 revenue of $12.566 million was below the $13.587 million consensus estimate, and diluted EPS was a $0.07 loss versus the expected $0.01 loss.
- Retina weakness remains material
- Retina revenue fell to $6.5 million from $8.0 million year over year, creating concentration and demand risk despite Cyclo G6 product-family growth of 19% to $3.9 million.
- Lower outlook and working-capital pressure
- The company lowered full-year 2026 revenue guidance to $51 million-$53 million from $53 million-$55 million and expects to use more working capital for inventory.
- Board and shareholder governance conflict
- The 10-Q identifies new board tensions involving the largest shareholder, Novel Inspiration International Co., Ltd.; the disclosure references the July 16, 2026 Form 8-K and warns of possible resignation of 1 or more directors, with potential effects on strategy and operating results.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.07
- Segment
- Retina revenue: $6.5 million, down from $8.0 million in the prior-year quarter
- Segment
- Cyclo G6 product-family revenue: $3.9 million, up 19% year over year
What they said about what is next.
Full-year 2026 revenue guidance is $51 million-$53 million, below the prior $53 million-$55 million outlook. Adjusted operating expense guidance remains $19 million-$19.5 million. Management expects to use more working capital for inventory.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 19, 2026
- IRIDEX reported Q1 2026 revenue of $11.8 million, slightly below prior year performance, while EPS improved to -$0.03. The company refocused on cost reductions, which helped mitigate deeper losses. However, challenges…
- 10-K · April 2, 2026
- IRIDEX reported fiscal 2025 revenue of $52.7 million (up from $48.7 million in fiscal 2024) while narrowing its net loss to $4.4 million in FY2025 from $8.9 million in FY2024. The company emphasizes its proprietary…
- 10-Q · November 12, 2025
- IRIDEX reported Q3 revenue of $12,484,000, up $903,000 versus Q3 2024 ($11,581,000). Gross margin contracted to ~32.2% (gross profit $4,013,000) while operating loss narrowed to $(1,411,000) and diluted net loss per…
- 10-Q · August 12, 2025
- IRIDEX reported Q2 revenue of $13.571M (up $0.94M vs Q2 2024) and GAAP diluted loss per share improved to $(0.06) from $(0.16) a year ago. Gross margin compressed to 34.5% while operating loss narrowed to $(0.94)M.…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing IRIX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever